Tanshinone Capsules Combined With Prednisone for Facial Seborrheic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Abstract

BackgroundFacial seborrheic dermatitis (FSD), also called facial seborrheic eczema, is a common disease affecting both male and female patients worldwide. Tanshinone is the main bioactive component extracted from the Traditional Chinese Medicine Salvia miltiorrhiza Bunge, which is widely used in treating skin inflammatory diseases. It is necessary to evaluate the clinical evidence for tanshinone capsule treatment of FSD. This study aimed to evaluate the safety and effectiveness of tanshinone capsules combined with prednisone in the treatment of facial seborrheic dermatitis and to provide evidence for clinical practice.MethodsStudies were searched in PubMed, the Cochrane Library, the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, the Chinese Scientific Journal Database, and WanFang Database before October 2021. We also searched for randomized controlled clinical trials (RCT) of tanshinone capsules combined with prednisone on facial seborrheic dermatitis. The meta-analysis was conducted according to the guidelines of the Cochrane Handbook. Two reviewers regulated the research selection, data extraction, and risk of bias assessment, respectively, and a third reviewer was used for consulting when necessary. Review Manager Software 5.3 was used for meta-analysis.ResultsA total of 10 RCTs with 916 participants were included. Nine studies reported total effectiveness, five studies reported symptom score, seven studies reported adverse events, and four studies reported recurrence rate. The duration of treatment was 4 to 8 weeks. Combination therapy showed better clinical effects compared to the prednisone (OR: 5.82; 95% CI: 3.53, 9.59; p < 0.00001). Combination therapy could repair skin lesions (MD: −0.40; 95% CI: −0.51, −0.30; p < 0.00001), reduce skin erythema (MD: −0.58, 95% CI: −0.67, −0.49; p < 0.00001), relieve skin itch (MD: −0.70; 95% CI −0.77, −0.63; p < 0.00001), and desquamation score (MD: −0.64; 95% CI: −0.71, −0.56; p < 0.00001). Furthermore, combination therapy could reduce adverse events (OR: 0.46; 95% CI: 0.26, 0.84; p = 0.01) and control recurrence rate (OR: 0.22; 95% CI: 0.13, 0.36; p < 0.00001).ConclusionsCompared with prednisone, tanshinone capsules combined with prednisone may be effective in the treatment of facial seborrheic dermatitis. However, due to the high risk and ambiguity of bias in the included trials, the conclusion of this study must be interpreted carefully.

Effectiveness of traditional Chinese medicine preparations for facial seborrheic dermatitis: case reports

“…A meta-analysis evaluated the safety and effectiveness of tanshinone capsules combined with prednisone in the treatment of facial seborrheic dermatitis. In comparison to prednisone, tanshinone capsules combined with prednisone may be more effective in the treatment of facial seborrheic dermatitis [ 10 ]. Another meta-analysis indicated that the treatment of FSD with the comedication of Chinese and Western medicines was significantly more effective than single use of Western medicine in terms of symptom score, skin physiological parameters, recurrence rate and incidence of adverse effects [ 11 ].…”